These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 24270242)

  • 1. Limelight on alpha-synuclein: pathological and mechanistic implications in neurodegeneration.
    Wales P; Pinho R; Lázaro DF; Outeiro TF
    J Parkinsons Dis; 2013; 3(4):415-59. PubMed ID: 24270242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. α-Synucleinopathy phenotypes.
    McCann H; Stevens CH; Cartwright H; Halliday GM
    Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1():S62-7. PubMed ID: 24262191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuropathology underlying clinical variability in patients with synucleinopathies.
    Halliday GM; Holton JL; Revesz T; Dickson DW
    Acta Neuropathol; 2011 Aug; 122(2):187-204. PubMed ID: 21720849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
    Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
    Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic comparison of the effects of alpha-synuclein mutations on its oligomerization and aggregation.
    Lázaro DF; Rodrigues EF; Langohr R; Shahpasandzadeh H; Ribeiro T; Guerreiro P; Gerhardt E; Kröhnert K; Klucken J; Pereira MD; Popova B; Kruse N; Mollenhauer B; Rizzoli SO; Braus GH; Danzer KM; Outeiro TF
    PLoS Genet; 2014 Nov; 10(11):e1004741. PubMed ID: 25393002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuropathological spectrum of synucleinopathies.
    Jellinger KA
    Mov Disord; 2003 Sep; 18 Suppl 6():S2-12. PubMed ID: 14502650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ɑ-Synuclein strains and seeding in Parkinson's disease, incidental Lewy body disease, dementia with Lewy bodies and multiple system atrophy: similarities and differences.
    Peelaerts W; Bousset L; Baekelandt V; Melki R
    Cell Tissue Res; 2018 Jul; 373(1):195-212. PubMed ID: 29704213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implication of Alpha-Synuclein Phosphorylation at S129 in Synucleinopathies: What Have We Learned in the Last Decade?
    Oueslati A
    J Parkinsons Dis; 2016; 6(1):39-51. PubMed ID: 27003784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
    Lee VM; Trojanowski JQ
    Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clusterin/apolipoprotein J is associated with cortical Lewy bodies: immunohistochemical study in cases with alpha-synucleinopathies.
    Sasaki K; Doh-ura K; Wakisaka Y; Iwaki T
    Acta Neuropathol; 2002 Sep; 104(3):225-30. PubMed ID: 12172907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of the novel A53E alpha-synuclein mutation on its oligomerization and aggregation.
    Lázaro DF; Dias MC; Carija A; Navarro S; Madaleno CS; Tenreiro S; Ventura S; Outeiro TF
    Acta Neuropathol Commun; 2016 Dec; 4(1):128. PubMed ID: 27938414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphorylated NUB1 distinguishes α-synuclein in Lewy bodies from that in glial cytoplasmic inclusions in multiple system atrophy.
    Tanji K; Miki Y; Mori F; Kon T; Kakita A; Takahashi H; Wakabayashi K
    Brain Pathol; 2019 Nov; 29(6):803-812. PubMed ID: 31006160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential Modes of Intercellular α-Synuclein Transmission.
    Valdinocci D; Radford RA; Siow SM; Chung RS; Pountney DL
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28241427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies.
    Wong YC; Krainc D
    Nat Med; 2017 Feb; 23(2):1-13. PubMed ID: 28170377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathological roles of α-synuclein in neurological disorders.
    Vekrellis K; Xilouri M; Emmanouilidou E; Rideout HJ; Stefanis L
    Lancet Neurol; 2011 Nov; 10(11):1015-25. PubMed ID: 22014436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic approaches in Parkinson's disease and related disorders.
    Valera E; Masliah E
    J Neurochem; 2016 Oct; 139 Suppl 1(Suppl 1):346-352. PubMed ID: 26749150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prominent astrocytic alpha-synuclein pathology with unique post-translational modification signatures unveiled across Lewy body disorders.
    Altay MF; Liu AKL; Holton JL; Parkkinen L; Lashuel HA
    Acta Neuropathol Commun; 2022 Nov; 10(1):163. PubMed ID: 36371251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Synucleinopathies: Twenty Years On.
    Goedert M; Jakes R; Spillantini MG
    J Parkinsons Dis; 2017; 7(s1):S51-S69. PubMed ID: 28282814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
    Olanow CW; Brundin P
    Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spectrum of abnormalities of sympathetic tyrosine hydroxylase and alpha-synuclein in chronic autonomic failure.
    Isonaka R; Sullivan P; Jinsmaa Y; Corrales A; Goldstein DS
    Clin Auton Res; 2018 Apr; 28(2):223-230. PubMed ID: 29396794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.